Striatal and nigral D1 mechanisms involved in the antiparkinsonian effects of SKF 82958 (APB): Studies of tremulous jaw movements in rats

Psychopharmacology

Volumn 143, Issue 1, 1999, Pages 72-81

  Mayorga, A J ^a   Trevitt, J T ^a   Conlan, A ^a   Gianutsos, G ^a   Salamone, J D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Acetylcholine; Caudate; Dopamine; Motor; Parkinsonism; Putamen; Substantia nigra

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 (4 HYDROXYPHENYL) 1H 3 BENZAZEPINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4,6,6A,7,8,12B HEXAHYDRO 7 METHYLINDOLO[4,3 AB]PHENANTHRIDINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTIPARKINSON AGENT; BICUCULLINE; DOPAMINE 1 RECEPTOR; PILOCARPINE; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; MUSCARINIC AGENT; SK&F 82958;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; GABAERGIC SYSTEM; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; JAW MOVEMENT; MALE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PUTAMEN; RAT; SUBSTANTIA NIGRA; ANIMAL; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; JAW; MOVEMENT (PHYSIOLOGY); NEOSTRIATUM; SPRAGUE DAWLEY RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPARKINSON AGENTS; BENZAZEPINES; BICUCULLINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GABA ANTAGONISTS; JAW; MALE; MOVEMENT; MUSCARINIC AGONISTS; NEOSTRIATUM; PILOCARPINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; SUBSTANTIA NIGRA;

EID: 0032588945     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050921     Document Type: Article

References (59)

1. 3H] gamma-aminobutyric acid in the basal ganglia or 6-hydroxydopamine lesioned rats. Neurosci Lett 121:233-236
2. Aceves J, Floran B, Sierra A, Mariscal S (1995) D-1 receptor mediated modulation of the release of gamma-aminobutyric acid by endogenous dopamine in the basal ganglia of the rat. Prog Neuropsychopharmacol Biol Psychiatr 19:7272-739
3. Adams RD, Victor M, Ropper AH (1996) Tremors, myoclonus, spasms and tics. In: Principles of Neurology. McGraw-Hill, New York, pp 69-77
4. 1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 273:309-314
5. 2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys. Jpn J Pharmacol 67:117-124
6. Aquilonius SM (1980) Cholinergic mechanisms in the CNS related to Parkinson's disease. In: Parkinson's disease - current progress, problems and management. Elsevier, North Holland, pp 17-27
7. Barbeau A (1986) Parkinson's disease: clinical features and etiopathology. In: Vinken, Bruyn, Klawans (eds) Handbook of clinical neurology, vol 5 (49): extrapyramidal disorders. Elsevier, North Holland, pp 87-152
8. 5 dopamine receptors in primate brain. J Neurosci 15:7821-7836
9. Bevan MD, Smith AD, Bolam JP (1996) The substantia nigra as a site of synaptic integration of functionally diverse information arising from the ventral pallidum and the globus pallidus in the rat. Neurosci Lett 75:5-12
10. 2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 40: 927-933
11. Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase T (1987) Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Transm 68:41-50
12. Buzsaki G, Smith A, Berger S, Fisher LJ, Gage FH (1990) Petit mal epilepsy and parkinsonian tremor: hypothesis of a common pacemaker. Neuroscience 36:1-14
13. 1 receptors facilitate transmitter release. Nature 366:344-347
14. Carriero DL, Outslay G, Mayorga AJ, Aberman J, Gianutsos G, Salamone JD (1997) Motor dysfunction produced by tacrine administration in rats. Pharmacol Biochem Behav 58:851-858
15. Close SP, Elliott PJ, Hayes AG, Marriott AS (1990) Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease, Psychopharmacology 102:295-300
16. Collins P, Broekkamp CLE, Jenner P, Marsden CD (1991) Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation. Psychopharmacology 103:503-512
17. Cousins MS, Carriero DL, Salamone JD (1997) Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs. Eur J Pharmacol 322: 137-145
18. Cousins MS, Atherton L, Salamone JD (1998a) Behavioral and electromyographic characterization of the local frequency of tacrine-induced tremulous jaw movements. Physiol Behav 64:153-158
19. Cousins MS, Finn M, Carriero DL, Conlan A, Salamone JD (1998b) The role of ventrolateral striatal acetylcholine in the production of tacrine-induced jaw movements: a neurochemical and behavioral study. Pharmacol Biochem Behav (in press)
20. DeBoer P, Abercrombie ED, Heeringa M, Westerink BHC (1993) Differential effect of systemic administration of bromocriptine and L-DOPA on the release of acetylcholine from striatum of intact and 6-OHDA-treated rats. Brain Res 608:198-203
21. Duvoisin RC (1967) Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 17:124-136
22. 1 agonist, CY 208-243, in de novo patients with Parkinson's disease. Mov Disord 7: 239-243
23. Factor SA, Weiner WJ (1988) The current clinical picture of Parkinson's disease. In: Hefty F, Weiner WJ (eds) Neurology. Plenum Press, New York, pp 1-9
24. Finn M, Jassen A, Baskin P, Salamone JD (1997a) Tremulous characteristics of the vacuous jaw movements induced by pilocarpine and ventrolateral striatal dopamine depletions. Pharmacol Biochem Behav 57:243-249
25. Finn M, Mayorga AJ, Conlan A, Salamone JD (1997b) Involvement of pallidal and nigral GABA mechanisms in the generation of tremulous jaw movements in rats. Neuroscience 80:235-244
26. 1 receptors stimulates the release of GABA in the basal ganglia of the rat. Neurosci Lett 116:136-140
27. 2 dopamine receptor regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432
28. 1 dopamine agonists with varying efficacies co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology 117:287-297
29. 1 receptors in the rat striatum in vivo. J Neurosci 17:5972-5978
30. Harbaugh RE, Roberts DW, Coombs DW, Saunders RL, Reeder TM (1984) Preliminary report: intracranial cholinergic drug infusion in patients with Alzheimer's disease. Neurosurgery 15:514-518
31. Hardie RJ, Lees AJ, Stern GM (1984) On-off fluctuations in Parkinson's disease. Brain 107:487-506
32. Jicha G, Salamone JD (1991) Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletions: possible model of parkinsonian symptoms. J Neurosci 11:3822-3829
33. Kelley AE, Bakshi VP, Delfs JM, Lang CG (1989) Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificity. Psychopharmacology 99:542-549
34. Löschmann PA, Smith LA, Lange KW, Jähnig P, Jenner P, Marsden CD (1992) Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology 109:1-2, 49-56
35. Mayorga AJ, Carierro DL, Cousins MS, Gianutsos G, Salamone JD (1997) Tremulous jaw movements produced by acute tacrine administration: possible relation to parkinsonian symptoms. Pharmacol Biochem Behav 56:273-279
36. McEvoy JP (1983) The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. J Clin Psychopharmacol 3:288-301
37. Nisenbaum E, Mermelstein PG, Wilson CJ, Surmier DJ (1998) Selective blockade of a slowly inactivating potassium current in striatal neurons by (±) 6-chloro-APB hydrobromide (SKF 82958). Synapse 29:213-224
38. Noring U, Povlesen UJ, Casey DE, Gerlach J (1984) Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drug-related parkinsonism. Psychopharmacology 84:569-571
39. Ott BR, Lannon MC (1992) Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol 15:322-325
40. Robertson GS, Robertson HA (1989) Evidence that L-DOPA-induced rotational behavior is dependent on both striatal and nigral mechanisms. J Neurosci 9:3326-3331
41. Salamone JD, Baskin P (1996) Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of parkinsonian tremor. Pharmacol Biochem Behav 53: 179-183
42. Salamone JD, Lalies MD, Channell SL, Iversen SD (1986) Behavioral and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat. Psychopharmacology 88:467-471
43. Salamone JD, Johnson, CJ, McCullough LD, Steinpreis RE (1990) Lateral striatal cholinergic mechanisms involved in oral motor activities in rats. Psychopharmacology 102:529-534
44. Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A (1998) Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol 56:1-21
45. Scheel-Kruger J, Magelund G, Olianas MC (1981) Role of GABA in the striatal output system: globus pallidus, nucleus entopeduncularis, substantia nigra and nucleus subthalamicus. Adv Biochem Psychopharmacol 30:165-186
46. Staude G, Wolf W, Ott M, Oertel WH, Dengler R (1995) Tremor as a factor in prolonged reaction times of parkinsonian patients. Move Disord 10:153-162
47. 1 receptor agonist in the rat. Neuropharmacology 36:93-99
48. 1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol 199:389
49. 1-mediated behavioral and electrophysiological effects. Synapse 23:280-291
50. Trevitt JT, Lyons M, Aberman J, Carriero D, Finn M, Salamone JD (1997) Effects of clozapine, thioridazine, risperidone and haloperidol on behavioral tests related to extrapyramidal motor function. Psychopharmacology 132:74-81
51. Trevitt JT, Atherton LA, Aberman J, Salamone JD (1998) Effects of subchronic administration of clozapine, thioridazine and haloperidol on tests related to extrapyramidal motor function. Psychopharmacology 137:61-66
52. 2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-henyl-1,2,3,6-tetrahydopyridine-lesioned parkinsonian monkeys. Move Disord 6: 664-672
53. Vila M, Herrero MT, Levy R, Faucheux B, Ruberg M, Guillen J, Luquin MR, Guridi J, Javoy-Agid F, Agid Y, Obeso JA, Hirsch EC (1996) Consequences of nigrostriatal denervation on the gamma-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes. Neurology 46:802-809
54. 1 receptor antagonist: binding characteristics and localization. Exp Neurol 111:145-151
55. 1 receptors: efficacy of full (dihydrexine) vs. partial (SKF38393) agonists in primates vs. rodents. Eur J Pharmacol 242:165-169
56. Weick BG, Engber TM, Susel Z, Chase TN, Walters JR (1990) Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration. Brain Res 523:16-22
57. 2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 65:709-730
58. Yurek DM, Hipkens SB (1993) Intranigral injections of SCH 23390 inhibit amphetamine-induced rotational behavior. Brain Res 623:56-64
59. Zigmond MJ, Stricker EM, Berger TW (1987) Parkinsonism: insights from animal models utilizing neurotoxic agents. In: Animal models of dementia. Liss, New York, pp 1-38